Boston Scientific stock

BSX · NYSE · USD

Compare Boston Scientific
$43.91Change from previous close: −0.97%Absolute change: −$0.43

Close · November 16, 2026

Price history

−56.85% over the period

1 year: from $101.76 (November 17, 2025) to $43.91 (November 16, 2026), −56.85%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026$43.91
October 30, 2026$41.98
September 30, 2026$43.65
August 31, 2026$48.30
July 31, 2026$46.73
June 30, 2026$42.68
May 29, 2026$48.31
April 30, 2026$57.61
March 31, 2026$62.75
February 27, 2026$76.85
January 30, 2026$93.53
December 31, 2025$95.35
November 28, 2025$101.58
November 17, 2025$101.76

At a glance

  • The company

    Develops and markets medical devices for interventional procedures in gastroenterology, cardiology, neurology, urology and oncology

  • Latest results

    Quarter to September 30, 2026 · EPS $0.73 (estimate $0.75)

TickerLandia's take on Boston Scientific

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$39.57
52-wk high$102.71

−57.25% from the 52-week high

Analysts · 31 analysts

Average target$49.60+12.96% vs. price

Buy 19 · Hold 12 · Sell 0 · Buy

TickerLandia Fingerprint: Boston Scientific

Compared with similar companies: very weak momentum.

Financials and price compared with 31 companies in the medical devices industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Boston Scientific is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Boston Scientific's P/E today is 22.6, below the median of its last 8 fiscal years (57.8; between 13.6 and 102.8 from 2016 to 2025). Boston Scientific's P/E (trailing 12 months): 18.7, −40% against the median of a group of 11 similar companies (31.4).

P/E compared with its history

Compared with 11 similar companies

Boston Scientific's metrics compared with similar companies
MetricBoston ScientificPosition in the groupBand
P/E (trailing 12 months)18.7Low
Forward P/E14.2Low
Operating margin19.6%Middle
ROE14.1%Middle
Debt/equity0.46Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Boston Scientific. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$5.44B

Latest quarter · Q2 2026

Net income

$907M

Latest quarter · Q2 2026

Quarterly net margin

16.7%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$64.27B
P/E
18.7
EPS
$2.37
Volume
9.7M
Daily trading
€800.7M
Dividend yield
0.00%

How Boston Scientific is changing

All results
  • Revenue grew 15.2% a year on average over the last 5 years

  • Operating margin rose from 13.0% to 18.0%

  • Profits turn into cash: free cash flow equal to 128% of net income

Returns

Boston Scientific returns

$1,000 invested in Boston Scientific 5 years ago, on November 16, 2021, would be worth $1,060 today: +6.01% in total, +1.17% per year. This is the price return only: dividends are excluded.

PeriodBoston ScientificS&P 500$1,000 becomes
1 month−1.08%−3.12%$989
6 months−16.65%+2.07%$834
Year to date−53.95%+10.46%$461
1 year−56.85%+13.33%$432
3 years−19.68%+67.73%$803
5 years+6.01%+60.86%$1,060
10 years+105.57%+247.35%$2,056

Over the last 6 months it has done better than 10% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Boston Scientific: technical analysis

Boston Scientific is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 59.4% below its all-time closing high ($108.14, September 8, 2025).

Trend
Downward
RSI (14 sessions)
49
Between 30 and 70
vs 200-session average
−18.53%

Support and resistance

Price areas where Boston Scientific has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$49.90+13.64%2 touches, last on September 2, 2026
  2. Resistance$47.07+7.20%2 touches, last on November 4, 2026
  3. Resistance$46.09+4.96%3 touches, last on October 23, 2026
  4. Last price$43.91
  5. Support$42.31−3.65%6 touches, last on October 8, 2026

Volatility and risk

Over the last year it has moved little with the S&P 500.

Beta (1 year) vs S&P 500
0.27
Volatility (60 sessions, annualised)
38.0%
Largest fall in the last year
−59.14%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Boston Scientific: seasonality

Average monthly price change over 35 years

+5.2%Jan−0.1%Feb+1.9%Mar+1.6%Apr+1.5%May+0.1%Jun+2.1%Jul+0.4%Aug−2.7%Sep−0.0%Oct−1.0%Nov+3.6%Dec

Over the last 35 years, the strongest month for Boston Scientific has been January: +5.19% on average, positive in 21 years out of 34. The weakest has been September: −2.74% on average, positive in 13 years out of 35. November, the current month, has been positive in 16 years out of 34 (−1.04% on average).

Show chart data
MonthAverageMedianPositive years
January+5.19%+6.93%21 of 34
February−0.14%+0.58%18 of 34
March+1.94%+0.35%19 of 34
April+1.57%+3.18%22 of 34
May+1.51%+2.03%20 of 34
June+0.14%−0.33%17 of 35
July+2.12%+3.49%22 of 35
August+0.42%−0.99%16 of 35
September−2.74%−3.90%13 of 35
October−0.01%−0.43%16 of 35
November−1.04%−0.19%16 of 34
December+3.63%+3.19%26 of 34

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Boston Scientific and its competitors

Boston Scientific organizes its medical devices into two segments, MedSurg and Cardiovascular, serving interventional specialties worldwide. The MedSurg range includes gastrointestinal tools such as biliary stent systems and SpyGlass single-use scopes, urological products such as ureteral stents and holmium laser systems, and spinal cord stimulators and deep brain stimulation systems for movement disorders and chronic pain.

Headquarters
Marlborough, United States
Employees
59,000
Founded
1979
Chief executive
Michael Mahoney
Boston Scientific and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Boston ScientificBSX$64.27B19.6%18.7−16.65%
Edwards LifesciencesEW$61.61B28.8%61.6+31.31%
GE HealthCare TechnologiesGEHC$37.8B13.8%17.7+37.99%
StrykerSYK$117.88B24.0%33.0+1.41%
MedtronicMDT$132.22B20.1%25.4+35.90%
DexComDXCM$31.08B24.0%32.8+33.33%

Same industry or related industries, similar size. Compare Boston Scientific with its competitors · Full profile